查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
鐮狀細胞疾病 (SCD) 治療的全球市場：市場規模、佔有率、成長分析、治療類型、最終用戶 - 產業預測，2023-2030 年
市場調查報告書
商品編碼
1396147

鐮狀細胞疾病 (SCD) 治療的全球市場：市場規模、佔有率、成長分析、治療類型、最終用戶 - 產業預測，2023-2030 年

Global Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment type(Pharmaceuticals and supportive care), By End user(Hospitals, clinics) - Industry Forecast 2023-2030
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2021年鐮狀細胞疾病（SCD）治療市場規模為17.3億美元，將從2022年的21億美元成長到2030年的99億美元，預測期間（2023-2030年）年複合成長率為21.4% 。預計將成長至1000萬美元。

全球鐮狀細胞疾病（SCD）治療市場是一個充滿活力且重要的市場，用於滿足鐮狀狀細胞疾病（SCD）患者的醫療需求。鐮狀細胞疾病（SCD）是一種遺傳性血液疾病，其特徵是血紅蛋白異常，導致紅血球變得僵硬並呈新月形，導致多種併發症和健康問題。該市場旨在開發創新治療方法、藥物和支持性護理，以提高 SCD 患者的生活品質。鐮狀細胞疾病（SCD）在世界各地的高盛行率，特別是在撒哈拉以南非洲、中東和亞洲的某些地區，迫切需要有效的治療方法。我強調這一點。

醫學研究的進步，包括基因治療和標靶藥物開發，正在為創新治療方法開闢新途徑。此外，人們對 SCD 及其影響的認知不斷提高，以及政府的配合措施和支持，正在推動研發投資。然而，也存在一些限制，特別是在低收入地區，例如醫療資源有限，阻礙了有效的診斷和治療。與先進治療方法相關的高成本和有限的報銷選擇可能會阻礙市場成長。該疾病的複雜性和對個體化治療方法的需求增加了醫療保健提供者和研究人員面臨的挑戰。主要市場趨勢包括精準醫療的興起和針對每位患者基因特徵個體化治療方案。製藥公司、研究機構和倡導團體之間的合作在追求創新治療方法方面越來越受到關注。市場開拓機會在於擴大服務欠缺地區的醫療保健覆蓋範圍、開發具有成本效益的治療方法以及探索基因編輯和幹細胞移植等新治療方法。隨著研發投資的增加、技術的進步以及對改善患者治療結果的關注，全球市場對於製藥公司、生物技術公司和醫療保健提供者來說變得越來越重要，以解決SCD 患者未得到滿足的需求。我們提供這是一個令人興奮的機會，可以對我們的應對措施產生重大影響。透過利用創新、協作和以患者為中心的方法的力量，這個市場有潛力改變數百萬人遭受這項挑戰的生活。

本報告的目標細分市場

全球鐮狀細胞疾病（SCD）治療市場根據治療類型、最終用戶和地區進行細分。依治療類型，市場分為藥物和支持性護理。依最終用戶分類，市場分為醫院、診所、研究機構等。依地區分類，分為北美、歐洲、亞太地區、中東/非洲、拉丁美洲。

促進因素

基因治療的進展

使用基因療法作為治療鐮狀細胞疾病（SCD）的有前景的方法已經取得了重大進展。 CRISPR-Cas9 等基因編輯技術的出現為糾正導致鐮狀細胞疾病 (SCD) 的潛在基因突變開闢了新途徑。 2020年，美國食品藥物管理局（FDA）核准了第一個針對SCD的基因療法Zynteglo。這種創新治療方法修改患者自身的幹細胞以產生健康的血紅蛋白，從而減輕疾病的症狀。基因療法的這些進展為鐮狀細胞疾病（SCD）更有效、更持久的治療帶來了希望。

抑制因素

醫療資源取得受限

儘管醫學取得了進步，但在確保獲得優質衛生服務方面仍然存在重大挑戰，特別是在鐮狀細胞疾病（SCD）流行的低收入地區。基礎設施不足、缺乏衛生設施以及缺乏訓練有素的專業人員阻礙了鐮狀細胞疾病 (SCD) 的有效診斷和治療。獲得醫療保健資源的機會有限會導致診斷延遲、併發症管理不善以及患者治療效果不佳。為了向鐮狀細胞疾病（SCD）患者提供及時、適當的醫療護理，必須解決醫療資源短缺的問題並加強醫療基礎設施。

市場趨勢：

個人化醫療與精準治療

鐮狀細胞疾病 (SCD) 治療的一個顯著趨勢是越來越重視個人化醫療。基因檢測和識別與鐮狀細胞疾病 (SCD) 相關的個體遺傳變異的進步正在促進量身定做的治療方法。例如，FDA核准用於治療 SCD 的羥基脲已被證明在不同患者中具有不同的反應。正在進行的研究和開發正在積極識別預測治療反應的生物標記和遺傳因素，為開發旨在改善治療結果的個體化治療方法鋪平道路。

目錄

  • 執行摘要
  • 調查方法
  • 母市場分析
  • 主要市場考察
    • 技術分析
    • 價格分析
    • 供應鏈分析
    • 價值鏈分析
    • 市場生態系統
    • 智慧財產權分析
    • 貿易分析
    • Start-Ups分析
    • 原料分析
    • 創新矩陣
    • 研發線產品分析
    • 總體經濟指標
    • 主要投資分析
    • 關鍵成功因素
    • 競爭程度
  • 市場動態及展望
    • 市場動態
      • 促進因素
      • 機會
      • 抑制因素
      • 任務
    • 監管形勢
    • 波特的分析
    • 對未來中斷的特殊考察
  • 鐮狀細胞疾病 (SCD) 治療的全球市場：依治療類型
    • 市場概況
    • 藥物和支持性護理
  • 鐮狀細胞疾病 (SCD) 治療的全球市場：按最終用戶分類
    • 市場概況
    • 醫院
    • 診所
    • 研究機構
    • 其他
  • 按地區分類的全球鐮狀細胞疾病 (SCD) 治療市場規模
    • 市場概況
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
      • 德國
      • 西班牙
      • 法國
      • 英國
      • 其他歐洲國家地區
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 其他亞太地區
    • 拉丁美洲
      • 巴西
      • 其他拉丁美洲地區
    • 中東和非洲 (MEA)
      • 海灣合作理事會國家
      • 南非
      • 其他中東/非洲地區
  • 競爭形勢
    • 前5名企業對比
    • 主要企業市場定位（2021年）
    • 主要市場參與者所採取的策略
    • 關鍵成功策略
    • 近期市集活動
    • 主要企業市場佔有率（2021年）
  • 主要企業簡介
    • Novartis（Switzerland）
    • Pfizer（US）
    • Global Blood Therapeutics（US）
    • Bluebird Bio（US）
    • Bristol Myers Squibb（US）
    • Sangamo Therapeutics（US）
    • Emmaus Life Sciences（US）
    • Eli Lilly and Company（US）
    • Modus Therapeutics（Sweden）
    • Gamida Cell（Israel）
    • Lonza Group（Switzerland）
    • Addmedica（France）
    • Selexys Pharmaceuticals（US）
    • GlycoMimetics（US）
    • Mast Therapeutics（US）
    • Acceleron Pharma（US）
    • Angiocrine Bioscience（US）
    • Imara Inc.（US）
    • AstraZeneca（UK）
    • Sanofi（France）
簡介目錄
Product Code: SQMIG35D2091

Sickle Cell Disease Treatment Market size was valued at USD 1.73 billion in 2021 and is poised to grow from USD 2.10 billion in 2022 to USD 9.91 billion by 2030, at a CAGR of 21.4% during the forecast period (2023-2030).

The Global Sickle Cell Disease Treatment Market is a dynamic and essential sector dedicated to addressing the medical requirements of individuals afflicted with sickle cell disease (SCD). SCD is a genetic blood disorder characterized by abnormal hemoglobin, leading to the deformation of red blood cells into rigid and crescent shapes, resulting in various complications and health issues. The market aims to develop innovative therapies, medications, and supportive care options to enhance the quality of life for individuals affected by SCD. The high prevalence of sickle cell disease globally, particularly in sub-Saharan Africa, the Middle East, and specific regions of Asia, underscores the pressing need for effective treatments.

Advancements in medical research, including gene therapy and targeted drug development, have opened new avenues for innovative treatment approaches. Additionally, increasing awareness about SCD and its impact, along with government initiatives and support, has fueled investments in research and development. Nevertheless, the market faces constraints such as limited access to healthcare resources, especially in low-income regions, hindering effective diagnosis and treatment. The high costs associated with advanced therapies and limited reimbursement options can impede market growth. The complex nature of the disease and the necessity for personalized treatment approaches contribute to the challenges faced by healthcare providers and researchers. Key trends in the market include the emergence of precision medicine and personalized treatment options tailored to individual patients' genetic profiles. Collaborations between pharmaceutical companies, research institutions, and advocacy groups have gained prominence in the pursuit of innovative therapies. Opportunities in the market lie in expanding access to healthcare in underserved regions, developing cost-effective treatments, and exploring novel therapeutic modalities such as gene editing and stem cell transplantation. With increasing investments in research and development, advancements in technology, and a growing focus on improving patient outcomes, the global market presents an attractive opportunity for pharmaceutical companies, biotechnology firms, and healthcare providers to make a significant impact in addressing the unmet needs of individuals living with SCD. By harnessing the power of innovation, collaboration, and patient-centric approaches, the market holds the potential to transform the lives of millions affected by this challenging disease.

Segments covered in this report

Global Sickle Cell Disease Treatment Market is segmented on the basis of treatment type, end user, and region. By treatment type, the market is segmented into pharmaceuticals and supportive care. By end user, the market is segmented into hospitals, clinics, research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers:

Advancements in Gene Therapy

Significant progress has been made in utilizing gene therapy as a promising approach for treating sickle cell disease. The advent of gene-editing technologies, such as CRISPR-Cas9, has opened new avenues for correcting the underlying genetic mutation responsible for SCD. In 2020, the U.S. Food and Drug Administration (FDA) approved Zynteglo, the first gene therapy for SCD. This innovative therapy involves modifying a patient's own stem cells to produce healthy hemoglobin, thereby reducing the symptoms of the disease. These advancements in gene therapy provide hope for more effective and enduring treatments for sickle cell disease.

Restraints

Limited Access to Healthcare Resources

Despite the strides in medical advancements, significant challenges persist in ensuring access to quality healthcare services, particularly in low-income regions where sickle cell disease is prevalent. Inadequate infrastructure, a shortage of healthcare facilities, and a lack of trained professionals impede the effective diagnosis and treatment of SCD. The limited access to healthcare resources contributes to delayed diagnosis, insufficient management of complications, and suboptimal patient outcomes. Addressing these resource gaps and enhancing healthcare infrastructure are essential to ensuring timely and appropriate care for individuals affected by sickle cell disease.

Market Trends:

Personalized Medicine and Precision Therapies

A noticeable trend in the management of sickle cell disease (SCD) is the increasing emphasis on personalized medicine. Progress in genetic testing and the comprehension of individual genetic variations linked to SCD have facilitated the adoption of tailored treatment approaches. For example, hydroxyurea, an FDA-approved medication for SCD, has exhibited varying responses among patients. Ongoing research is actively identifying biomarkers and genetic factors to predict treatment responses, paving the way for the development of personalized treatment regimens that aim for enhanced outcomes.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
    • Regulatory Landscape
    • Porters Analysis
      • Competitive rivalry
      • Threat of Substitute Products
      • Bargaining Power of Buyers
      • Threat of New Entrants
      • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
      • Political Impact
      • Economic Impact
      • Social Impact
      • Technical Impact
      • Environmental Impact
      • Legal Impact
  • Global Sickle Cell Disease Treatment Market by Treatment type
    • Market Overview
    • Pharmaceuticals and supportive care
  • Global Sickle Cell Disease Treatment Market by End user
    • Market Overview
    • Hospitals
    • clinics
    • research institutes
    • and others
  • Global Sickle Cell Disease Treatment Market Size by Region
    • Market Overview
    • North America
      • USA
      • Canada
    • Europe
      • Germany
      • Spain
      • France
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
      • By Development
      • By Company
      • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Novartis (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Pfizer (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Global Blood Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bluebird Bio (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bristol Myers Squibb (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sangamo Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Emmaus Life Sciences (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Eli Lilly and Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Modus Therapeutics (Sweden)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Gamida Cell (Israel)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Lonza Group (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Addmedica (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Selexys Pharmaceuticals (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • GlycoMimetics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Mast Therapeutics (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Acceleron Pharma (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Angiocrine Bioscience (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Imara Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • AstraZeneca (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sanofi (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments